Role of human pregnane X receptor in tamoxifenand 4-hydroxytamoxifen- mediated CYP3A4 induction in primary human hepatocytes and LS174T cells

Drug Metabolism and Disposition

Volumn 36, Issue 5, 2008, Pages 946-954

  Sane, Rucha S ^a,b   Buckley, Donna J ^a   Buckley, Arthur R ^a   Nallani, Srikanth C ^a,c   Desai, Pankaj B ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; CYTOCHROME P450 3A4; ESTROGEN RECEPTOR ALPHA; GLUCOCORTICOID RECEPTOR ALPHA; NORTAMOXIFEN; PHENOBARBITAL; PREGNANE X RECEPTOR; RIFAMPICIN; SMALL INTERFERING RNA; STEROID RECEPTOR COACTIVATOR 1; TAMOXIFEN;

ARTICLE; CELL CULTURE; COLON CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG RESEARCH; ENZYME INDUCTION; HUMAN; HUMAN CELL; LIVER CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION INITIATION;

CELL LINE, TUMOR; CELLS, CULTURED; CYTOCHROME P-450 CYP3A; ESTROGEN RECEPTOR ALPHA; HEPATOCYTES; HUMANS; RECEPTORS, GLUCOCORTICOID; RECEPTORS, STEROID; RNA, MESSENGER; RNA, SMALL INTERFERING; TAMOXIFEN; TRANSFECTION;

EID: 42449116209     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.018598     Document Type: Article

References (40)

1. Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, Jin Y, Storniolo AM, Nikoloff DM, Wu L, et al. (2006) Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80:61-74.
2. Bowen WP, Carey JE, Miah A, McMurray HF, Munday PW, James RS, Coleman RA, and Brown AM (2000) Measurement of cytochrome P450 gene induction in human hepatocytes using quantitative real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 28:781-788.
3. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, and Mitchell JB (1987) Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47:936-942.
4. Cotreau MM, von Moltke LL, Harmatz JS, and Greenblatt DJ (2001) Molecular and pharmacokinetic evaluation of rat hepatic and gastrointestinal cytochrome p450 induction by tamoxifen. Pharmacology 63:210-219.
5. de Cremoux P, Bieche I, Tran-Perennou C, Vignaud S, Boudou E, Asselain B, Lidereau R, Magdelénat H, Becette V, Sigal-Zafrani B, et al. (2004) Inter-laboratory quality control for hormone-dependent gene expression in human breast tumors using real-time reverse transcription-polymerase chain reaction. Endocr Relat Cancer 11:489-495.
6. Desai PB, Nallani SC, Sane RS, Moore LB, Goodwin BJ, Buckley DJ, and Buckley AR (2002) Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4OHT. Drug Metab Dispos 30:608-612.
7. Ding XF, Anderson CM, Ma H, Hong H, Uht RM, Kushner PJ, and Stallcup MR (1998) Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): multiple motifs with different binding specificities. Mol Endocrinol 12:302-313.
8. Dowsett M, Cuzick J, Howell A, and Jackson I (2001) Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial. Br J Cancer 85:317-324.
9. Dowsett M, Pfister C, Johnston SR, Miles DW, Houston SJ, Verbeek JA, Gundacker H, Sioufi A, and Smith IE (1999) Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer. Clin Cancer Res 5:2338-2343.
10. El-Sankary W, Plant NJ, Gibson GG, and Moore DJ (2000) Regulation of the CYP3A4 gene by hydrocortisone and xenobiotics: role of the glucocorticoid and pregnane X receptors. Drug Metab Dispos 28:493-496.
11. Gibson GG, Plant NJ, Swales KE, Ayrton A, and El Sankary W (2002) Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man. Xenobiotica 32:165-206.
12. Goodwin B, Hodgson E, and Liddle C (1999) The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol Pharmacol 56:1329-1339.
13. Hartley DP, Dai X, He YD, Carlini EJ, Wang B, Huskey SE, Ulrich RG, Rushmore TH, Evers R, and Evans DC (2004) Activators of the rat pregnane X receptor differentially modulate hepatic and intestinal gene expression. Mol Pharmacol 65:1159-1171.
14. Hashimoto H, Toide K, Kitamura R, Fujita M, Tagawa S, Itoh S, and Kamataki T (1993) Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control. Eur J Biochem 218:585-595.
15. Haugen BR, Larson LL, Pugazhenthi U, Hays WR, Klopper JP, Kramer CA, and Sharma V (2004) Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids. J Clin Endocrinol Metab 89:272-280.
16. Huang L, Wring SA, Woolley JL, Brouwer KR, Serabjit-Singh C, and Polli JW (2001) Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metab Dispos 29:754-760.
17. Kisanga ER, Gjerde J, Guerrieri-Gonzaga A, Pigatto F, Pesci-Feltri A, Roberson C, Serrano D, Pelosi G, Decensi A, and Lien EA (2004) Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial. Clin Cancer Res 10:2336-2343.
18. Kocarek TA, Shenoy SD, Mercer-Haines NA, and Runge-Morris M (2002) Use of dominant negative nuclear receptors to study xenobiotic-inducible gene expression in primary cultured hepatocytes. J Pharmacol Toxicol Methods 47:177-187.
19. Li T and Chiang JY (2006) Rifampicin induction of CYP3A4 requires pregnane X receptor cross talk with hepatocyte nuclear factor 4alpha and coactivators, and suppression of small heterodimer partner gene expression. Drug Metab Dispos 34:756-764.
20. Lien EA, Solheim E, and Ueland PM (1991) Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res 51:4837-4844.
21. Lopez GN, Webb P, Shinsako JH, Baxter JD, Greene GL, and Kushner PJ (1999) Titration by estrogen receptor activation function-2 of targets that are downstream from coactivators. Mol Endocrinol 13:897-909.
22. Maglich JM, Stoltz CM, Goodwin B, Hawkins-Brown D, Moore JT, and Kliewer SA (2002) Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol Pharmacol 62:638-646.
23. Matsunaga T, Maruyama M, Harada E, Katsuyama Y, Sugihara N, Ise H, Negishi N, Ikeda U, and Ohmori S (2004) Expression and induction of CYP3As in human fetal hepatocytes. Biochem Biophys Res Commun 318:428-434.
24. Min G, Kim H, Bae Y, Petz L, and Kemper JK (2002) Inhibitory cross-talk between estrogen receptor (ER) and constitutively activated androstane receptor (CAR). CAR inhibits ER-mediated signaling pathway by squelching p160 coactivators. J Biol Chem 277:34626-34633.
25. Mnif W, Pascussi JM, Pillon A, Escande A, Bartegi A, Nicolas JC, Cavaillès V, Duchesne MJ, and Balaguer P (2007) Estrogens and antiestrogens activate hPXR. Toxicol Lett 170:19-29.
26. Mouly S, Lown KS, Kornhauser D, Joseph JL, Fiske WD, Benedek IH, and Watkins PB (2002) Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther 72:1-9.
27. Oakley RH, Jewell CM, Yudt MR, Bofetiado DM, and Cidlowski JA (1999) The dominant negative activity of the human glucocorticoid receptor beta isoform. Specificity and mechanisms of action. J Biol Chem 274:27857-27866.
28. Ogg MS, Williams JM, Tarbit M, Goldfarb PS, Gray TJ, and Gibson GG (1999) A reporter gene assay to assess the molecular mechanisms of xenobiotic-dependent induction of the human CYP3A4 gene in vitro. Xenobiotica 29:269-279.
29. Pascussi JM, Busson-Le Coniat M, Maurel P, and Vilarem MJ (2003a) Transcriptional analysis of the orphan nuclear receptor constitutive androstane receptor (NR1I3) gene promoter: identification of a distal glucocorticoid response element. Mol Endocrinol 17:42-55.
30. Pascussi JM, Gerbal-Chaloin S, Drocourt L, Maurel P, and Vilarem MJ (2003b) The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. Biochim Biophys Acta 1619:243-253.
31. Pascussi JM, Drocourt L, Fabre JM, Maurel P, and Vilarem MJ (2000) Dexamethasone induces pregnane X receptor and retinoid X receptor-alpha expression in human hepatocytes: synergistic increase of CYP3A4 induction by pregnane X receptor activators. Mol Pharmacol 58:361-372.
32. Pascussi JM, Drocourt L, Gerbal-Chaloin S, Fabre JM, Maurel P, and Vilarem MJ (2001) Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor. Eur J Biochem 268:6346-6358.
33. Pujols L, Mullol J, Roca-Ferrer J, Torrego A, Xaubet A, Cidlowski JA, and Picado C (2002) Expression of glucocorticoid receptor alpha- and beta-isoforms in human cells and tissues. Am J Physiol Cell Physiol 283:C1324-C1331.
34. Raddatz D, Middel P, Bockemuhl M, Benohr P, Wissmann C, Schworer H, and Ramadori G (2004) Glucocorticoid receptor expression in inflammatory bowel disease: evidence for a mucosal down-regulation in steroid-unresponsive ulcerative colitis. Aliment Pharmacol Ther 19:47-61.
35. Schuetz EG, Schmid W, Schutz G, Brimer C, Yasuda K, Kamataki T, Bornheim L, Myles K, and Cole TJ (2000) The glucocorticoid receptor is essential for induction of cytochrome P-4502B by steroids but not for drug or steroid induction of CYP3A or P-450 reductase in mouse liver. Drug Metab Dispos 28:268-278.
36. Singleton DW, Feng Y, Burd CJ, and Khan SA (2003) Nongenomic activity and subsequent c-fos induction by estrogen receptor ligands are not sufficient to promote deoxyribonucleic acid synthesis in human endometrial adenocarcinoma cells. Endocrinology 144:121-128.
37. Tegude H, Schnabel A, Zanger UM, Klein K, Eichelbaum M, and Burk O (2007) Molecular mechanism of basal CYP3A4 regulation by hepatocyte nuclear factor 4α: evidence for direct regulation in the intestine. Drug Metab Dispos 35:946-954.
38. Tirona RG, Lee W, Leake BF, Lan LB, Cline CB, Lamba V, Parviz F, Duncan SA, Inoue Y, Gonzalez FJ, et al. (2003) The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat Med 9:220-224.
39. Westlind-Johnsson A, Malmebo S, Johansson A, Otter C, Andersson TB, Johansson I, Edwards RJ, Boobis AR, and Ingelman-Sundberg M (2003) Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos 31:755-761.
40. Xie W, Barwick JL, Downes M, Blumberg B, Simon CM, Nelson MC, Neuschwander-Tetri BA, Brunt EM, Guzelian PS, and Evans RM (2000) Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature 406:435-439.